Acadia Pharmaceuticals Inc. (ACAD) announced that the FDA has approved DAYBUE STIX for oral solution for the treatment of Rett syndrome in adult and pediatric patients two years of age and older
DAYBUE STIX is a dye- and preservative-free powder formulation of trofinetide that caregivers can mix with a variety of water-based liquids, allowing easy adjustment of taste and dose. It provides the same efficacy and safety profile as the original DAYBUE oral solution.
Rett syndrome is a rare neurodevelopmental disorder that affects approximately 6,000 to 9,000 patients in the U.S., typically caused by mutations in the MECP2 gene. Children often experience normal early development before regressing in communication and motor skills, with lifelong care required.
The FDA approval was supported by bioequivalence data showing comparable exposure between DAYBUE STIX and DAYBUE, as well as efficacy and safety results from the Phase 3 LAVENDER study. Patients treated with DAYBUE demonstrated meaningful reductions in Rett syndrome symptoms compared to placebo.
Safety data indicated that DAYBUE STIX was generally well tolerated.
DAYBUE STIX will be available on a limited basis in Q1 2026, with broader availability expected early in Q2 2026. The original oral solution formulation will remain on the market.
DAYBUE delivered $101.1 million in Q3 2025 revenue, up 11% year-over-year.
ACAD has traded between $13.40 and $27.73 over the past year. The stock is currently trading at $26.75, up 0.26%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.